*The Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) investigation included 2 multicenter, double-masked, placebo-controlled, randomized clinical trials. Eligible patients had subfoveal choroidal neovascularization (CNV) lesions caused by AMD with greatest linear dimension on the retina measuring 5400 μm or less, with evidence of classic CNV and best-corrected visual acuity between 20/40 and 20/200 on the Snellen chart. Patients were randomized to receive treatment with verteporfin or a placebo. The primary outcome was the proportion of eyes with fewer than 15 letters (approximately 3 lines) of visual acuity loss at the Month 24 examination compared with baseline.¹
†Progression defined as classic CNV beyond the area identified at baseline.¹